• Human CLL-1/MICL/CD371 protein (Recombinant) (C-His) (STJP001098)

Human CLL-1/MICL/CD371 protein (Recombinant) (C-His) (STJP001098)

SKU:
STJP001098

Current Stock:
Host: HEK293 cells
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Formulation: Lyophilised from a 0.22 Mu m filtered solution of PBS, pH 7.4.
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Determination Method: < 0.1 EU/Mu g of the protein by LAL method.
Gene Symbol: CLEC12A
Gene ID: 160364
Uniprot ID: CL12A_HUMAN
Immunogen: Recombinant Human CLL-1/MICL/CD371 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (His75-Ala275) of human CLEC12A (Accession #NP_001193939.1) fused with a 6×His tag at the C-terminus.
Immunogen Sequence: HVTLKIEMKKMNKLQNISEE LQRNISLQLMSNMNISNKIR NLSTTLQTIATKLCRELYSK EQEHKCKPCPRRWIWHKDSC YFLSDDVQTWQESKMACAAQ NASLLKINNKNALEFIKSQS RSYDYWLGLSPEEDSTRGMR VDNIINSSAWVIRNAPDLNN MYCGYINRLYVQYYHCTYKK RMICEKMANPVQLGSTYFRE A
Tissue Specificity Preferentially expressed in lymphoid tissues and immune cells, including natural killer (NK) cells, T-cells, dendritic cells and monocytes or macrophages. Detected in spleen macrophage-rich red pulp and in lymph node (at protein level). Detected in peripheral blood leukocytes, dendritic cells, bone marrow, monocytes, mononuclear leukocytes and macrophages.
Post Translational Modifications Phosphorylated at Tyr-7 by SRC in the ITIM motif following ligand-binding, promoting recruitment of tyrosine-protein phosphatases PTPN6 and PTPN11. Highly N-glycosylated.glycosylation varies between cell types.
Function Myeloid inhibitory C-type lectin receptor that acts as a negative regulator of myeloid cell activation. Myeloid cell inhibition is required to limit proinflammatory pathways and protect against excessive inflammation. Specifically recognizes and binds various structures, such as neutrophil extracellular traps (NETs) or monosodium urate crystals. Also acts as a pattern-recognition receptor for pathogen-associated molecules, such as plasmodium hemozoin or mycobacterial micolic acid. Ligand-binding induces phosphorylation of its ITIM motif, followed by recruitment of tyrosine-protein phosphatases PTPN6 and PTPN11, which counteract tyrosine-protein kinase SYK, thereby preventing myeloid cell activation. Acts as a pattern-recognition receptor for NETs in neutrophils: specifically recognizes DNA in NETs, leading to inhibit neutrophil activation and limit further NET formation. This regulation is essential for controlling key neutrophil responses and limit NET-mediated inflammatory conditions. Also recognizes dead cells by acting as a receptor for monosodium urate crystals, leading to down-regulate neutrophil activation. Binding to monosodium urate crystals also promotes the type I interferon response. Acts as an inhibitor of natural killer (NK) cell cytotoxicity. Also acts as an ihibitor of dendritic cell maturation in an IL10-dependent manner.
Protein Name C-Type Lectin Domain Family 12 Member A
C-Type Lectin-Like Molecule 1
Cll-1
Dendritic Cell-Associated Lectin 2
Dcal-2
Killer Cell C-Type Lectin-Like Receptor L1
Hklrl1
Myeloid Inhibitory C-Type Lectin-Like Receptor
Micl
Cd Antigen Cd371
Database Links Reactome: R-HSA-6798695
Cellular Localisation Cell Membrane
Single-Pass Type Ii Membrane Protein
Ligand Binding Leads To Internalization
Clusters At Phagocytic Vesicles Upon Monosodium Urate Crystal-Binding
Alternative Protein Names C-Type Lectin Domain Family 12 Member A protein
C-Type Lectin-Like Molecule 1 protein
Cll-1 protein
Dendritic Cell-Associated Lectin 2 protein
Dcal-2 protein
Killer Cell C-Type Lectin-Like Receptor L1 protein
Hklrl1 protein
Myeloid Inhibitory C-Type Lectin-Like Receptor protein
Micl protein
Cd Antigen Cd371 protein
CLEC12A protein
CLL1 protein
DCAL2 protein
KLRL1 protein
MICL protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance